(0.25%) 5 144.25 points
(0.15%) 38 499 points
(0.38%) 17 913 points
(-0.62%) $83.33
(0.78%) $1.938
(0.03%) $2 347.80
(0.27%) $27.61
(2.46%) $944.75
(-0.22%) $0.933
(-0.27%) $11.00
(-0.38%) $0.797
(1.30%) $93.07
@ $38.32
发出时间: 15 Feb 2024 @ 04:08
回报率: -30.72%
上一信号: Feb 14 - 04:48
上一信号:
回报率: -0.52 %
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
今日成交量 | 275 687 |
平均成交量 | 486 820 |
市值 | 714.60M |
EPS | $0 ( 2024-03-07 ) |
下一个收益日期 | ( $-1.190 ) 2024-06-13 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | -23.71 |
ATR14 | $0.0320 (0.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
2023-12-15 | Sassine Andy | Buy | 75 000 | Employee Stock Option (right to buy) |
2023-12-15 | Chivukula Pad | Buy | 125 000 | Employee Stock Option (right to buy) |
2023-12-15 | Kurata Lance | Buy | 75 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
78.05 |
Last 97 transactions |
Buy: 2 555 134 | Sell: 1 046 972 |
音量 相关性
Arcturus Therapeutics 相关性 - 货币/商品
Arcturus Therapeutics 财务报表
Annual | 2023 |
营收: | $157.75M |
毛利润: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
营收: | $157.75M |
毛利润: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
营收: | $205.76M |
毛利润: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
营收: | $12.36M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.12 | -- |
Div. Sustainability Score | 1.571 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.165 | 1.500 | -3.31 | -4.96 | [0 - 0.5] |
returnOnAssetsTTM | -0.0619 | 1.200 | -2.06 | -2.48 | [0 - 0.3] |
returnOnEquityTTM | -0.0907 | 1.500 | -2.12 | -3.18 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.72 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.62 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.23 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0704 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -92.63 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.392 | -0.784 | [0 - 20] |
debtEquityRatioTTM | 0.108 | -1.500 | 9.57 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.341 | 1.000 | 7.65 | 7.65 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.442 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.596 | 1.000 | -4.42 | -4.42 | [0.2 - 2] |
assetTurnoverTTM | 0.375 | 0.800 | -0.836 | -0.668 | [0.5 - 2] |
Total Score | 1.571 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -26.59 | 1.000 | -2.79 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0907 | 2.50 | -1.362 | -3.18 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.784 | 2.00 | -0.261 | -0.784 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.677 | 2.00 | -0.226 | -0.451 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.444 | 1.500 | -6.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.112 | 1.000 | -5.30 | 0 | [0.1 - 0.5] |
Total Score | -2.19 |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。